The Growing Debate Over Popular Weight-Loss Drugs

In recent years, a group of medications known as GLP-1s has changed the way many people manage their health. These drugs, which include well-known names like Ozempic and Wegovy, mimic a hormone that helps control blood sugar levels and reduces hunger. According to The Guardian, these medications are now used by half a million people in Australia alone. In the United States, a recent analysis by Gallup suggests that more than one in ten Americans are taking a GLP-1 drug for weight loss. While these drugs offer hope for many, they have also become the center of intense debate regarding safety and fair access.

For some patients, the experience with these drugs has been life-changing in a negative way. Todd Engel, a man from Maryland who took Ozempic for diabetes, reported a sudden and total loss of vision in his right eye. His doctor diagnosed him with NAION, a condition caused by a lack of blood flow to the eye. According to NPR, Engel later lost vision in his left eye as well. He has now joined other patients in filing lawsuits against Novo Nordisk, the manufacturer of Ozempic. These lawsuits claim that the company failed to warn patients and doctors about the potential risk of serious eye complications.

However, the link between these drugs and such health problems is not yet proven. NPR reports that while some research has shown a higher rate of eye issues among diabetic patients taking semaglutide—the active ingredient in these drugs—medical groups remain careful. The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have stated that current studies cannot confirm that the medication is the direct cause of these conditions. They argue that more detailed research is needed before drawing firm conclusions. For now, these organizations do not recommend that patients stop taking their prescribed medication.

While some are concerned about safety, others are fighting for wider access. In Australia, advocates for women with a hormonal condition called PMOS—formerly known as polycystic ovarian syndrome—are calling for these drugs to be covered by the government. PMOS affects one in eight women and can lead to weight gain, irregular periods, and a higher risk of diabetes. Currently, these patients often have to pay for the medication themselves, which can cost hundreds of dollars each month. Lorna Berry, a spokesperson for the Polyendrocrine Metabolic Ovarian Syndrome Association of Australia, told The Guardian that it is important for people to have fair access to these treatments, regardless of their financial situation.

Not everyone agrees that GLP-1s are the best solution for every condition, though. Associate Professor Magdalena Simonis, a spokesperson for the Royal Australasian College of Physicians, noted that these drugs are expensive and may not be the only tool available for managing conditions like PMOS. She also pointed out that women’s health issues have historically been left out of government funding changes. As a result, there is an ongoing conversation about whether these medications should be subsidized for a broader range of patients or if other treatments should be prioritized.

For the pharmaceutical companies involved, the path forward involves complex negotiations. Novo Nordisk is currently working with health departments in various countries to try to get their drugs listed on government-subsidized programs. A company spokesperson told The Guardian that they remain committed to improving access for eligible patients living with obesity. Meanwhile, the legal system continues to examine the safety reports. The Food and Drug Administration in the U.S. keeps a database of adverse events—reports of harmful side effects—which serves as a starting point for regulators to decide if drug labels need to be updated with new warnings.

Ultimately, the story of GLP-1 drugs is one of both promise and uncertainty. Millions of people rely on them to manage chronic health conditions, yet the legal and medical communities are still working to understand the full range of their effects. As research continues and more data becomes available, patients and doctors will have to weigh the benefits of these treatments against the potential risks. For now, the focus remains on gathering more evidence and ensuring that those who need these medications the most can afford them safely.